RTP Mobile Logo
Select Publications

Adams S et al. Current landscape of immunotherapy in breast cancer: A review. JAMA Oncol 2019;[Online ahead of print]. Abstract

Adams S. Dramatic response of metaplastic breast cancer to chemo-immunotherapy. NPJ Breast Cancer 2017;3:8. Abstract

Ali HR et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol 2015;26(7):1488-93. Abstract

Cortes J et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. ASCO 2020;Abstract 1000.

D’Abreo N, Adams S. Immune-checkpoint inhibition for metastatic triple-negative breast cancer: Safety first? Nat Rev Clin Oncol 2019;16(7):399-400. Abstract

Dieci MV et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study. Ann Oncol 2015;26(7):1518. Abstract

Emens LA et al. IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. ESMO 2020;Abstract LBA16.

Hamm CA et al. Genomic and immunological tumor profiling identifies targetable pathways and extensive CD8+/PDL1+ immune infiltration in inflammatory breast cancer tumors. Mol Cancer Ther 2016;15(7):1746-56. Abstract

Harbeck N et al. IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC). ESMO 2020;Abstract LBA11.

Luen S et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast 2016;29:241-50. Abstract

Schmid P et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020;382(9):810-21. Abstract

Schmid P et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379(22):2108-21. Abstract